scispace - formally typeset
Search or ask a question
Institution

Johns Hopkins University School of Medicine

HealthcareBaltimore, Maryland, United States
About: Johns Hopkins University School of Medicine is a healthcare organization based out in Baltimore, Maryland, United States. It is known for research contribution in the topics: Population & Cancer. The organization has 44277 authors who have published 79222 publications receiving 4788882 citations.


Papers
More filters
Journal ArticleDOI
TL;DR: There is increasing evidence that secreted vesicles play important roles in numerous aspects of biology, contribute to many human diseases and have significant biotechnological potential and also highlighted some vexing problems related to their nomenclature.
Abstract: There is increasing evidence that secreted vesicles play important roles in numerous aspects of biology (e.g. intercellular vesicle traffic, immunity, development, neurobiology and microbiology), contribute to many human diseases (e.g. cancer, neurodegenerative disorders and HIV/AIDS) and have significant biotechnological potential. This expanding interest in extracellular vesicles has also highlighted some vexing problems related to their nomenclature. At the first meeting of the International Society for Extracellular Vesicles (ISEV) in Gothenburg, Sweden (April 2012), the authors chaired a session on the issue of vesicle nomenclature. (Published: 15 February 2013) Citation: Journal of Extracellular Vesicles 2013, 2 : 20389 - http://dx.doi.org/10.3402/jev.v2i0.20389

762 citations

Journal ArticleDOI
TL;DR: The yeast Sir2 protein, required for transcriptional silencing, has an NAD+dependent histone deacetylase (HDA) activity that is eliminated in a yeast strain from which SIR2 and its four homologs have been deleted as mentioned in this paper.
Abstract: The yeast Sir2 protein, required for transcriptional silencing, has an NAD+-dependent histone deacetylase (HDA) activity. Yeast extracts contain a NAD+-dependent HDA activity that is eliminated in a yeast strain from which SIR2 and its four homologs have been deleted. This HDA activity is also displayed by purified yeast Sir2p and homologous Archaeal, eubacterial, and human proteins, and depends completely on NAD+ in all species tested. The yeast NPT1 gene, encoding an important NAD+ synthesis enzyme, is required for rDNA and telomeric silencing and contributes to silencing of the HM loci. Null mutants in this gene have significantly reduced intracellular NAD+ concentrations and have phenotypes similar to sir2 null mutants. Surprisingly, yeast from which all five SIR2 homologs have been deleted have relatively normal bulk histone acetylation levels. The evolutionary conservation of this regulated activity suggests that the Sir2 protein family represents a set of effector proteins in an evolutionarily conserved signal transduction pathway that monitors cellular energy and redox states.

761 citations

Journal ArticleDOI
TL;DR: This review documents the changing perspectives on the function of fatty-acid synthase and fatty- acid synthesis in human tumor biology and may provide new diagnostic and therapeutic moieties for patient care.

761 citations

Journal ArticleDOI
TL;DR: Triple therapy with fluticasone furoate, umeclidinium, and vilanterol resulted in a lower rate of moderate or severe COPD exacerbations than flutic asonefuroate–vilanterol or u meclid inium–vilAnterol in this population.
Abstract: Background The benefits of triple therapy for chronic obstructive pulmonary disease (COPD) with an inhaled glucocorticoid, a long-acting muscarinic antagonist (LAMA), and a long-acting β2-agonist (LABA), as compared with dual therapy (either inhaled glucocorticoid–LABA or LAMA–LABA), are uncertain. Methods In this randomized trial involving 10,355 patients with COPD, we compared 52 weeks of a once-daily combination of fluticasone furoate (an inhaled glucocorticoid) at a dose of 100 μg, umeclidinium (a LAMA) at a dose of 62.5 μg, and vilanterol (a LABA) at a dose of 25 μg (triple therapy) with fluticasone furoate–vilanterol (at doses of 100 μg and 25 μg, respectively) and umeclidinium–vilanterol (at doses of 62.5 μg and 25 μg, respectively). Each regimen was administered in a single Ellipta inhaler. The primary outcome was the annual rate of moderate or severe COPD exacerbations during treatment. Results The rate of moderate or severe exacerbations in the triple-therapy group was 0.91 per year, as...

760 citations

Journal ArticleDOI
10 Apr 2013-JAMA
TL;DR: In this retrospective multicenter study, the presence of the BRAF V600E mutation was significantly associated with increased cancer-related mortality among patients with PTC, and the association was not independent of tumor features.
Abstract: Importance BRAF V600E is a prominent oncogene in papillary thyroid cancer (PTC), but its role in PTC-related patient mortality has not been established. Objective To investigate the relationship between BRAF V600E mutation and PTC-related mortality. Design, Setting, and Participants Retrospective study of 1849 patients (1411 women and 438 men) with a median age of 46 years (interquartile range, 34-58 years) and an overall median follow-up time of 33 months (interquartile range, 13-67 months) after initial treatment at 13 centers in 7 countries between 1978 and 2011. Main Outcomes and Measures Patient deaths specifically caused by PTC. Results Overall, mortality was 5.3% (45/845; 95% CI, 3.9%-7.1%) vs 1.1% (11/1004; 95% CI, 0.5%-2.0%) (P Conclusions and Relevance In this retrospective multicenter study, the presence of the BRAF V600E mutation was significantly associated with increased cancer-related mortality among patients with PTC. Because overall mortality in PTC is low and the association was not independent of tumor features, how to use BRAF V600E to manage mortality risk in patients with PTC is unclear. These findings support further investigation of the prognostic and therapeutic implications of BRAF V600E status in PTC.

760 citations


Authors

Showing all 44754 results

NameH-indexPapersCitations
Robert Langer2812324326306
Bert Vogelstein247757332094
Solomon H. Snyder2321222200444
Steven A. Rosenberg2181204199262
Kenneth W. Kinzler215640243944
Hagop M. Kantarjian2043708210208
Mark P. Mattson200980138033
Stuart H. Orkin186715112182
Paul G. Richardson1831533155912
Aaron R. Folsom1811118134044
Gonçalo R. Abecasis179595230323
Jie Zhang1784857221720
Daniel R. Weinberger177879128450
David Baker1731226109377
Eliezer Masliah170982127818
Network Information
Related Institutions (5)
University of California, San Francisco
186.2K papers, 12M citations

99% related

Baylor College of Medicine
94.8K papers, 5M citations

99% related

University of Texas Southwestern Medical Center
75.2K papers, 4.4M citations

98% related

National Institutes of Health
297.8K papers, 21.3M citations

98% related

University of Alabama at Birmingham
86.7K papers, 3.9M citations

97% related

Performance
Metrics
No. of papers from the Institution in previous years
YearPapers
2023149
2022622
20216,078
20205,107
20194,444
20183,848